Evaluating the safety of COYA 302 for the treatment of ALS
In people with amyotrophic lateral sclerosis (ALS), faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.
Status
Recruiting